FDA to require Eli Lilly to add NAION vision-loss warning to GLP-1 diabetes and weight-loss drugs

 

• FDA cites potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare vision-loss condition, with Lilly GLP-1 drugs.
• ATTAIN-OSA Phase 3 Foundayo trial significantly improved obstructive sleep apnea severity and related risk factors.
• Eli Lilly plans U.S. FDA submission for Foundayo in obstructive sleep apnea by end of 2026.
• Jefferies raises Eli Lilly price target to $1,700 from $1,610, a Street-high level for the stock.
• Jefferies cites larger-than-expected international obesity drug market potential and strength of the company’s GLP‑1 portfolio.

https://finviz.com/stock?t=LLY&p=d